Facebook
X
LinkedIn
Forward2026 Endocrinology Grand Rounds | An Update on Recommendations for Screening, Diagnosis and Management of Primary Hyperaldosteronism – Endocrine Society Clinical Practice Guidelines July 2025
Primary hyperaldosteronism remains significantly underdiagnosed and underrated despite its known risks for cardiovascular complications. The 2016 Endocrine Society guidelines focused on diagnosis and management, but the condition remains overlooked, underscoring the need for improved screening practices and updated management strategies. Bridging this educational gap involves raising awareness among healthcare providers, enhancing screening protocols, and refining treatment approaches to better identify and manage the condition effectively.
The activity is necessary as primary hyperaldosteronism remains underdiagnosed and underestimated, contributing to increased cardiovascular risks due to untreated cases. The new guidelines, released in July 2025, offer updated screening and management strategies, yet many healthcare providers are not familiar with these recent changes. The activity will enhance detection rates and improve patient outcomes.
Target Audience
Physicians, endocrinologists and healthcare providers interested in the subject matter.
Learning Objectives
- Utilize appropriate screening methods for individuals with primary hyperaldosteronism (PA).
- Identify the best testing methods to determine an appropriate treatment approach.
- Implement appropriate therapies for individuals with PA.
- Discuss possible barriers and biases which may impact patient care (i.e., race, ethnicity, language, gender identity/orientation, age, socioeconomic status, attitudes, feelings, or other characteristics).
Virtual Meeting- Zoom
An Nguyen, MD Assistant Clinical Professor, Department of Diabetes, Endocrinology and Metabolism, City of Hope
Presenter: Dr. Nguyen has indicated that there are no relevant financial relationships with ineligible companies.
Planner: Pooja Manroa, MD has indicated that there are no relevant financial relationships with ineligible companies.
This presentation and/or comments will provide a balanced, non-promotional, and evidence-based approach to all diagnostic, therapeutic and/or research related content.
CME Committee/Reviewer no relevant financial relationships: Daneng Li, MD
ACCREDITATION STATEMENT: City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CREDIT DESIGNATION: City of Hope designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The following credit type(s) are being offered for this course:
• AMA PRA Category 1 Credit™ 1.0
The following may apply AMA PRA Category 1 Credit™ for license renewal:
Registered Nurses: Nurses may report up to 1.0 credit hours toward the continuing education requirements for license renewal by their state Board of Registered Nurses (BRN). AMA PRA Category 1 Credit™ may be noted on the license renewal application in lieu of a BRN provider number.
Physician Assistants: The National Commission on Certification of Physicians Assistants states that AMA PRA Category 1 Credit™ accredited courses are acceptable for CME requirements for recertification.
Available Credit
- 1.00 AMA PRA Category 1 Credit™City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
City of Hope designates this 2026 Endocrinology Grand Rounds | An Update on Recommendations for Screening, Diagnosis and Management of Primary Hyperaldosteronism – Endocrine Society Clinical Practice Guidelines July 2025 for a maximum of 1.00 AMA PRA Category 1 Credit™ requirements. Physicians should claim only the credit commensurate with the extent of their participation in the activity. - 1.00 Attendance